[Deal Inside] SD Biosensor maintains Asta acquisition strategy…expects business synergy

SD Biosensor will proceed with its planned KRW 32.8 billion acquisition of Asta’s largest shareholder, despite Asta’s stock trading halt after an adverse audit opinion.

The company aims to combine Asta’s MALDI-TOF mass spectrometry technology with SD Biosensor’s global sales network and operating capabilities.

The deal is meant to expand SD Biosensor beyond medical diagnostics into semiconductor and secondary-battery analysis markets.

SD Biosensor also plans to provide funding and management support as Asta addresses accounting issues and works through listing eligibility reviews.